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Cigarette smoking (CS), the main risk factor for COPD (chronic obstructive pulmonary dis-
ease) in developed countries, decreases alveolar macrophages (AM) clearance of both apo-
ptotic cells and bacterial pathogens. This global deficit of AM engulfment may explain why
active smokers have worse outcomes of COPD exacerbations, episodes characterized by
airway infection and inflammation that carry high morbidity and healthcare cost. When
administered as intravenous supplementation, the acute phase-reactant alpha-1 antitrypsin
(A1AT) reduces the severity of COPD exacerbations in A1AT deficient (AATD) individuals
and of bacterial pneumonia in murine models, but the effect of A1AT on AM scavenging
functions has not been reported. Apoptotic cell clearance (efferocytosis) was measured in
human AM isolated from patients with COPD, in primary rat AM or differentiated monocytes
exposed to CS ex vivo, and in AM recovered from mice exposed to CS. A1AT (100 μg/mL,
16 h) significantly ameliorated efferocytosis (by ~50%) in AM of active smokers or AM
exposed ex vivo to CS. A1AT significantly improved AM global engulfment, including phago-
cytosis, even when cells were simultaneously challenged with apoptotic and Fc-coated
(bacteria-like) targets. The improved efferocytosis in A1AT-treated macrophages was asso-
ciated with inhibition of tumor necrosis factor-α converting enzyme (TACE) activity,
decreased mannose receptor shedding, and markedly increased abundance of efferocyto-
sis receptors (mannose- and phosphatidyl serine receptors and the scavenger receptor B2)
on AM plasma membrane. Directed airway A1AT treatment (via inhalation of a nebulized
solution) restored in situ airway AM efferocytosis after CS exposure in mice. The
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amelioration of CS-exposed AM global engulfment may render A1AT as a potential therapy
for COPD exacerbations.
Introduction
Alveolar macrophages isolated from the lungs of cigarette smokers or those with CS-related
COPD exhibit impaired clearance of pathogens (phagocytosis) and apoptotic cells (efferocyto-
sis) [1, 2]. Whereas AM pathogen clearance is important for resolution of airway infection,
removal of apoptotic cells ensures resolution of inflammation and repair [1]. The global dys-
function of AM engulfment in smokers and COPD patients may be most damaging during
acute infectious exacerbations, episodes of increased airway infection and inflammation dur-
ing which AM have to scavenge an increased load of both bacterial and apoptotic targets [3].
Given the high morbidity and mortality, as well as healthcare cost associated with COPD and
COPD exacerbations [4, 5], therapies aimed at improving AM scavenging functions are of
clinical importance.
AATD individuals have a higher risk of airways disease, including infectious exacerbations
[6], suggesting an airway-protective effect of the anti-proteinase A1AT. In addition, in AATD
patients augmentation of A1AT levels via intravenous administration of purified human pro-
tein reduces sputum levels of pro-inflammatory cytokines [7] and the severity of exacerbations
[5, 8]. A protective airway effect of A1AT has also been demonstrated in non-AATD experi-
mental model, where A1AT-overexpressing mice had reduced lung tissue damage following
lung bacterial infections [9], and A1AT administration suppressed the AM release of pro-
inflammatory mediators in CS-exposed mice [10]. The airway-protective effect of A1AT may
indeed be due to its effects on AM and monocytes, since A1AT treatment profoundly affects
peripheral blood monocyte derived macrophages (PBMDM) inflammatory response in a
dose- and time-dependent manner. Whereas low A1AT concentrations and short exposure
times increase TNF-α, IL-8, and IL-1β release, physiologic A1AT concentrations (correspond-
ing to normal A1AT circulating levels; 500 μg/mL) or prolonged exposures (18 h) reduce pro-
inflammatory cytokine secretion [11]. However, the effect of A1AT on AM engulfment of bac-
terial or apoptotic targets has not been reported.
Pathogens’ engulfment during phagocytosis begins with target recognition, a step that
involves pathogen opsonization with complement or immunoglobulins and specific recogni-
tion by highly conserved complement receptors such as C1R, CD11b or the immunoglobulin
receptor complex, such as FcγRI-III [12]. The abundance of these membrane receptors can be
regulated by membrane proteases [13]. Since A1AT inhibits the sheddase TACE (ADAM17)
[14], A1AT may play a specific role in maintaining the expression of FcγRI-III phagocytosis
receptors on AM plasma membrane. This notion is supported by the finding that A1AT
decreases the expression of several other phagocytosis receptors such as TLR4, and TLR2 on
LPS-stimulated islet macrophages [14, 15].
Apoptotic targets’ engulfment (efferocytosis) occurs via a plethora of scavenger receptors
that bind directly, or via a ligand (e.g. Gas-6 or protein S) to phosphatidylserine (PS) residues
expressed on apoptotic cells’ plasma membrane [16]. The major scavenger receptors impli-
cated in the AM engulfment of apoptotic targets include the mannose receptor (MAR,
CD206), the macrophage receptor with collagenous structure (MARCO, SCARB-2), PS recep-
tor (PSR), thrombospondin receptor (CD36), LDL receptor-related protein (CD91), hyal-
uronic acid receptor (CD44), and recognition molecules such as integrins [1]. These receptors
A1AT improves cigarette smoke-exposed macrophages engulfment
PLOS ONE | https://doi.org/10.1371/journal.pone.0176073 April 27, 2017 2 / 17
Competing interests: We acknowledge a potential
financial competing interest as Dr. Irina Petrache
has received a research grant from Baxter
Healthcare to cover the purchase of human-derived
A1AT product (Aralast NP). Dr. Irina Petrache does
not have any other competing financial or non-
financial interests with Baxter Healthcare. Baxter
Healthcare did not have any role in the study
design; collection, analysis, and interpretation of
data; writing of the paper; or decision to submit for
publication. This does not alter our adherence to
PLOS ONE policies on sharing data and materials.
may also be susceptible to protease cleavage that can in turn be modulated by A1AT, but these
studies or the effect of A1AT on AM efferocytosis in general has, to our knowledge, not been
reported yet.
Although AM from smokers or subjects with COPD are inefficient in clearing apoptotic
cells, the engagement in efferocytosis polarizes them towards an anti-inflammatory phenotype,
with increased local production of M-CSF, IL-4, IL-13, and IL-33 [17]. However, an excessive
AM anti-inflammatory phenotype impairs phagocytosis and clearance of pathogens such as
S. pneumococcus [18], decreasing antibacterial response in the murine lung. In turn, the effect
of disproportionate AM phagocytic/ pro-inflammatory polarization on efferocytosis function
has not been reported. During infectious exacerbations, the airways may simultaneously con-
tain differently polarized AM populations whose function may be further confounded by
active CS exposure. Furthermore, active CS exposure induces posttranslational modifications
of the A1AT native molecule (e.g. cleavage and oxidation of the catalytic site), causing an
“acquired” functional A1AT- deficient state [19–21]. These studies suggest that supplementa-
tion with native A1AT may be required to achieve functionally normal A1AT levels in COPD
individuals, even if they do not have genetic AATD.
In this study we used complementary approaches to investigate whether exogenous supple-
mentation of native A1AT enhances AM efferocytosis during CS exposure, without detrimen-
tal effects on phagocytosis. Our results indicate that A1AT treatment significantly improves
AM efferocytosis and phagocytosis, associated with TACE-inhibition and increase in specific
scavenging receptor membrane expression. Moreover we demonstrate that when concomi-
tantly exposed to Fc-coated “bacteria-like” and apoptotic targets, A1AT-treated AM exhibit
increased overall scavenging activity.
Preliminary results of our studies have been previously presented in the form of abstracts.
Material and methods
Reagents
Reagents, including LPS and rabbit anti-JMJD6 (PSR) antibody, were purchased from Sigma-
Aldrich (St. Louis, MO, USA) unless otherwise specified. Aralast NP and Prolastin C was from
Baxter International Inc. (Chicago, IL, USA) and Grifols (LA, CA, USA), respectively. Phorbol
12-myristate 13-acetate (PMA), rabbit anti-MAR antibody, rabbit anti-iNOS antibody, rabbit
polyclonal anti-GAPDH, mouse monoclonal anti-vinculin were from Abcam (Cambridge,
MA, USA), rabbit anti-SRB-2 antibody was from Santa Cruz Biotechnology (Dallas, TX, USA),
mouse anti-human CD3 was from BD Biosciences (Franklin Lakes, NJ, USA), recombinant rat
IL-4 was from ProSpec-Tany TechnoGene (Ness-Ziona, Israel), and TNF-α Protease Inhibi-
tor-1 (TAPI-1) was from ESD Millipore (Billerica, MA, USA).
Human subjects
Healthy non-smokers (n = 4) and smokers (n = 6) subjects were consented for research bron-
choscopy. Written consent was obtained per study protocol. IRB at Indiana University, India-
napolis, IN approved this protocol. COPD was defined based on GOLD 2007 criteria using the
FEV1/FVC ratio <70% to define obstruction and post-bronchodilator FEV1 to define the
obstruction severity (mild to moderate <80% but>50%; severe to very severe<50% predicted
FEV1). Individuals classified as GOLD stage 0 were active smokers with FEV1/FVC>70% but
with clinical symptoms of chronic bronchitis or dyspnea on exertion. Current smoker (n = 2),
ex-smoker (n = 1), and healthy non-smoker (n = 1) de-identified human lungs that were not
used for organ-transplantation with a PaO2/FiO2 ratio of>225, a clinical history and chest
X-ray diagnosis that did not indicate infection, and limited time on a ventilator from the
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University of Colorado Donor Alliance were used for ex-vivo bronchoalveolar lavage (BAL).
We noted the age, gender, smoking history, and cause of death. The Committee for the Protec-
tion of Human Subjects at National Jewish Health, Denver, CO approved this research. AATD
individuals (PiZZ genotype, n = 3) were enrolled in the clinical study “Effect of Double Dose
of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation” at the University of
Miami, Miami, FL (ClinicalTrials.gov Identifier: NCT01669421). AATD patients underwent
bronchoscopy with BAL after a single- (60 mg/kg, weekly administration at visit 1 and 3) or
double dose (120 mg/kg, weekly administration at visit 2) A1AT therapy (Zemaira, CSL Beh-
ring). Written consent was obtained per study protocol. IRB at the University of Miami,
Miami, FL approved this research.
During research bronchoscopy bronchoalveolar lavage (BAL) of right middle lobe or lingua
was performed with 100–240 mL sterile 0.9% saline. The BAL cells were pelleted by centrifuga-
tion and then plated in RPMI media supplemented with 1% non-essential amino acids, 2%
sodium pyruvate, 20mM Hepes, penicillin (100 U/ ml), and streptomycin (0.1 mg/ml) for 2 h
before being used in experiments. The non-adherent cells were discarded. The adherent
human AM were used in assays as described below.
Animal experiments
All experiments were conducted in compliance with the Institutional Animal Care and Use
Committee guidelines of Indiana University. Male Sprague-Dawley rats (8-16-week old, 400–
600 g, n = 60) were obtained from Charles River Laboratories (Wilmington, MA, USA). BAL
was performed as previously described. Briefly, rats were anesthetized with isoflurane and
euthanized by bilateral pneumothorax. After neck dissection and midline tracheostomy the
BAL needle was secured in place and 10 mL cold sterile 0.9% NaCl was instilled and recovered
three times. Cells in the BAL fluid were pelleted by centrifugation (300xg, 8 min) and then
maintained in DMEM supplemented with 10% heat-inactivated FBS, 1% penicillin and strep-
tomycin. Prior to experiments and treatments the medium was changed to low-serum (2%
FBS) DMEM.
Eight to ten-week-old male C57B/l6 mice from Charles River Laboratories (Wilmington,
MA, USA) were exposed to cigarette smoke in a total body exposure chamber (TE-10Z, Teague
Enterprises, Woodland, CA, USA) for 3 hours (n = 13) or for 5 hours/day, 5 days/week, for 6
months (n = 10) or to similar duration of ambient air (n = 21). Research-grade cigarettes
(1R3F, Kentucky Tobacco Research and Development Center, Lexington, KY, USA) were
smoked at a rate that achieved 90–120 ng/m3 microparticles in the exposure chamber. The
mice received aerosolized PBS or human A1AT using a micropump nebulizer (AeronebLab,
Aerogen, Inc.) 24 h prior to a brief (3 h) episode of cigarette smoke exposure or daily for the
last 7 days of a long-term (6-months) CS exposure. The day of experiment the mice received
intratracheal apoptotic thymocytes via oropharyngeal aspiration (10X106 cells/mouse). After 1
h mice were anesthetized with isoflurane, euthanized by bilateral pneumothorax, and BAL was
performed.
Cells
Primary human AM obtained from the BAL fluid of healthy subjects or smokers were cultured
in RPMI-1640 supplemented with 1% non-essential amino-acids, 2% sodium pyruvate, 20mM
Hepes, and penicillin (100 U/ ml).
Primary human AM obtained from the BAL fluid of AATD individuals underwent centri-
fugation (300 g, 8 min), were washed two times with sterile PBS, and lysed using Triton-X lysis
buffer. Cell lysates were saved at -80˚C until used for Western blotting.
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Primary rat AM obtained from BAL of Sprague-Dawley rats were cultured in DMEM
medium (Life Technologies, Grand Island, NY, USA) containing 10% heat-inactivated fetal
bovine serum (FBS), and penicillin (100U/mL) and streptomycin (0.1 mg/mL) and acclima-
tized for 2–3 days in the incubator at 37˚C, 5% CO2. One hour prior to the A1AT treatments
the primary rat cells were changed to low serum (2% FBS) medium.
Rat AM (cell line NR8383, ATCC Manassas, VA) were cultured in Ham’s F12K medium
(ATCC) containing L-glutamine (2 mM), sodium bicarbonate (1.5 g/L), and 15% heat-inacti-
vated FBS and maintained in the incubator at 37˚C, 5% CO2. One-day prior the experiments
the NR8383 cells were plated in 6-well plates (0.5 X 106 cells/well) or 100 mm Petri dishes
(2X106 cells/dish). One hour prior to the A1AT treatments the NR8383 AM were changed to
low serum (2% FBS) medium.
Human T-cells (acute T-cell leukemia cell line, Jurkat, ATCC) were cultured in RPMI-1640
supplemented with 10% heat-inactivated FBS, penicillin (100 U/ ml), and streptomycin (0.1
mg/ml).
Human monocytes (cell line THP-1, ATCC) were cultured in RPMI-1640 supplemented
with 10% heat-inactivated FBS, 2 mercaptoethanol (0.05 mM), penicillin (100 U/ ml), and
streptomycin (0.1 mg/ml). Monocyte-derived macrophages were obtained by differentiation
with PMA (100nM, 72 h).
CS extract preparation
Aqueous CS extract (100%) was prepared from filtered research-grade cigarettes (1R3F, Ken-
tucky Tabaco Research and Development Center, Lexington, KY, USA). Similarly, the air
control extract (AC) was prepared by bubbling ambient air into sterile PBS, as previously
described [22]. The final concentrations of CS and AC extracts used in cell culture experiments
ranged from 3% (primary rat AM) to 10% (NR8383 and THP-1 cell lines). At these concentra-
tions, CS extract inhibited AM proliferation, but did not affect AM viability, as assessed by
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) proliferation assay or
Annexin V staining (data not shown). Exposure time to AC or CS extract was 4 h. Post-expo-
sure the cell culture media was removed and low serum media (2% FBS) with or without
A1AT (100 μg/mL) was added.
Polymerized A1AT preparation
Polymers of A1AT were prepared as previously described by incubating Aralast NP A1AT pro-
tein (5 mg/mL) in phosphate buffered saline (PBS) at 60˚C for 2 h [21, 23].
Efferocytosis assays
In situ efferocytosis was assessed in mice that received via oropharyngeal aspiration fluores-
cently labeled apoptotic thymocytes (10X106 cells/mouse) [24]. The efferocytosis index was
measured after 1 h using flow cytometry, and was expressed as the percentage of AM recovered
in the BAL fluid that engulfed labeled thymocytes. Ex vivo efferocytosis assay was performed as
previously described [25]. Briefly, AM were co-incubated with apoptotic targets (1:5, unless
otherwise specified) for 1 h at 37˚C. Apoptotic targets were Jurkat cells (T-cell line) that were
fluorescently-labeled with Cell Tracker Orange (CTO, 0.5 mM, 30 min, 37˚C, Life Technolo-
gies, Grand Island, NY, USA), and then exposed to UV radiation (30,000 μJ/cm2) using a HL-
2000 HybriLinker, followed by incubation for 3.5 h at 37˚C, 5% CO2 in serum-free media. At
the end of co-incubation (1 h) with apoptotic Jurkat cells, AMs were collected in flow-cytome-
try tubes. The extracellular fluorescence (of membrane-bound but non-engulfed apoptotic tar-
gets) was quenched with trypan blue (Sigma; 1000μl; 0.04% in PBS)[25, 26]. Cells were then
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fixed in 1% paraformaldehyde. Engulfment efficiency was measured by flow cytometry using
Cytomics FC500 cytofluorimeter with CXP software (Beckman Coulter, Fullerton, CA).
Phagocytosis assay
Phagocytosis assay was performed by co-incubation of AM with phagocytic “Fc-coated” opso-
nized targets for 1 h at 37˚C at 1:5 ratio, unless otherwise specified. We used two types of
phagocytic targets: a) fluorescently-labeled latex beads (Sigma, Saint Louis, MO, USA) coated
with 1% BSA for 1 h at 4˚C and then incubated with rabbit anti-bovine albumin antibody
(1:500, 30 min, 37˚C; or b) Cell Tracker Green (CTG, 0.5mM, 30 min, 3˚C, Life Technologies,
Grand Island, NY, USA)-labeled Jurkats coated with mouse IgG2a anti-human CD3 antibody
(10 μl/mL, 30 min, 37˚C). At the end of co-incubation with phagocytic targets, AM were col-
lected in flow-cytometry tubes and engulfment was measured by flow cytometry.
TNF- α converting enzyme (TACE) activity
TNF- α converting enzyme (TACE) activity was measured in the human monocyte THP-1
membrane fractions using SensoLyte 520 TACE Activity Assay Kit (Anaspec, Fremont, CA,
USA) as per manufacturer’s instructions.
Western blotting
Cells were harvested in RIPA lysis buffer. Cytosolic and membrane fractions were extracted
with the membrane protein extraction kit (Biovision, Milpitas, CA, USA), using the manufac-
turer protocol. Whole cell lysates or membrane fractions were loaded in equal amounts, as
determined by BCA protein analysis (Pierce). We used equal volumes of cell supernatants after
concentration using 50μm columns (Millipore, Tullagreen, Carrigtwohill, Co. Cork, IRL). Pro-
teins were separated by SDS-PAGE and transferred onto a PVDF membrane followed by
immunoblotting. The chemiluminescent signal was detected using ECL-plus (Amersham, NJ,
USA) and normalized using anti-vinculin (1:5000) or -GAPDH (1:5000) antibody.
ELISA
Supernatants from AM cultures were concentrated using VWR columns (VWR, Radnor, PA,
USA). TNF-α was measured by ELISA (R&D Systems, Minneapolis, MN, USA), as per manu-
facturer’s protocol.
Statistical analysis
Statistical analysis was performed in Prism (GraphPad Software, San Diego, CA), using
unpaired Student t-test, 1-way or 2-way ANOVA, as appropriate. Statistical significance was
accepted at p<0.05.
Results
Effect of native and polymerized A1AT on efferocytosis in CS-exposed
AM
Primary AM isolated via BAL from individuals who were either never smokers or active smok-
ers (demographic and clinical characteristics listed in Table 1) were tested for efferocytosis by
co-incubation with apoptotic targets. As expected, AM from active smokers exhibited signifi-
cantly impaired efferocytosis compared to AM from non-smokers (Fig 1A). The effect of
A1AT on efferocytosis was tested after supplementation of AM cultures with purified human
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A1AT (100 μg/mL, 4 h or 16 h) prior to the addition of apoptotic cells. A1AT treatment for 16
h significantly increased efferocytosis of AM isolated from active smokers by ~50% (Fig 1A).
Of note, shorter A1AT treatment (4 h) was insufficient to improve efferocytosis of these cells
(Fig 1A). Treatment with A1AT for either 4 h or 16 h had no additional effect on efferocytosis
efficiency of AM isolated from non-smokers, suggesting that either efferocytosis was maximal
in cells from healthy individuals, or that cells from smokers were more likely to respond to
A1AT treatment.
This effect of A1AT on AM efferocytosis was recapitulated in models of ex vivo CS- expo-
sure. As we previously reported, CS (3%-10% v/v, 4 h) significantly inhibited efferocytosis in
primary rat AM (Fig 1B) and in the NR8383 AM (Fig 1C). Immediately after CS-exposure
A1AT treatment (100 μg/mL, 16 h) significantly improved efferocytosis of primary (Fig 1B)
and NR8383 (Fig 1C) AM exposed to CS.
To compare the A1AT effect on CS-exposed AM efferocytosis with a known efferocytosis
activator, we used IL-4, a potent activator of AM polarization towards an anti-inflammatory
phenotype. Indeed, IL-4 treatment restored the efferocytosis function of CS-exposed AMs to
that of control cells (Fig 1C). A1AT treatment (100 μg/mL, 16 h) increased AM efferocytosis
index by a similar level of magnitude (Fig 1C), but had no additive effect on IL-4 stimulated,
CS-exposed AMs (Fig 1C).
We then compared the effect of polymerized A1AT (pA1AT) with that of native A1AT on
CS-exposed AM efferocytosis. A1AT polymers were generated by heating A1AT (5mg/mL) in
10 mL sterile PBS at 60˚C for 2 h [21, 23]. In contrast to the effect of native A1AT, similar con-
centrations and duration of exposure to pA1AT failed to rescue CS-exposed NR8383 AM effer-
ocytosis (Fig 1D).
Effect of nebulized A1AT on AM in situ efferocytosis in mice exposed to
CS
To investigate the effect of A1AT on AM efferocytosis in vivo, C57BL/6J mice were exposed to
CS for short- (3 h) or long term (6 months), followed by challenge with exogenous apoptotic
targets. As previously reported [24], CS exposures decreased AM efferocytosis compared with
Table 1. Patient demographic, clinical, and functional characteristics.
Healthy Smokers at risk COPD AATD
(PiZZ)
Number 5 6 3 3
Gender (M, %) 80 50 100 100
Age (years) 40 ± 11.3 37 ± 12.1 52 ± 3.7 53.5 ± 10.5
Race (W, %) 40 83 33 100
Smoking status (ex-smoker/never smoker) 0/2 6/0 2/1 2/1
Smoking history (PY) 1.5 ± 2 12.5 ± 4.5 29.3 ± 7 30 ± 21
FEV1 (%predicted) NA NA 73 ± 10.2 48.1 ± 14.2
GOLD stage (0/1-2/3-4) NA 6/0/0 0/3/0 0/1/2







BAL fluid cell count (X107 cells/mL) 2.6 ± 1.1 15.1 ± 10.3 NA NA
Data are presented as mean ± SD or percentage (%). Abbreviations: AATD: alpha-1 antitrypsin deficiency; PiZZ—homozygous for A1AT gene Z mutation;
PY: pack-year; FEV1: forced expiratory volume in 1 s; GOLD: the Global initiative for chronic Obstructive Lung Disease; A1AT: alpha-1 antitrypsin; BAL:
broncho-alveolar lavage
https://doi.org/10.1371/journal.pone.0176073.t001
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ambient air-exposed mice (Fig 2). Native A1AT alveolar delivery was achieved via inhalation
of a nebulized solution [27]. A1AT (25 mg/mouse; ~0.1 mg/kg) either as a single administra-
tion 24 h prior to brief CS-exposure, or as a daily administration for seven consecutive days
during last week of a long-term CS-exposure significantly increased AM engulfment compared
to mice that received control vehicle (PBS) treatments (Fig 2). These results validated our ex-
vivo results of improved efferocytosis in CS- and A1AT-treated AM. Since efferocytosis
requires the participation of specific recognition receptors, and since recent reports implicate
Fig 1. Native and polymerized A1AT ex-vivo effect on CS-exposed AM efferocytosis. A. Absolute efferocytosis index
representing % of cells that engulfed fluorescently labeled apoptotic targets among AM isolated from active smokers (dark circles)
compared to those from healthy non-smokers (light gray circles). Native A1AT (Aralast NP, 100 μg/mL, 16 h) significantly increased
efferocytosis in AM from smokers (dark gray circles), but not in those from healthy non-smokers (gray squares). 1-way ANOVA, Sidak’s
multiple comparisons test, * p<0.05. B-C. Relative efferocytosis index representing % of AM that engulfed fluorescently labeled
apoptotic targets following indicated exposures, when compared to those exposed to control media. Primary rat AM (B) or NR8383 AM
(C) were exposed ex-vivo to AC or CS (4h, 3% or 10%, respectively, 4 h), native A1AT (Aralast NP, 100 μg/mL, 16 h), and compared to
IL-4 (20 ng/mL, 72 h). D. Polymerized A1AT (Aralast NP, 100 μg/mL, 16h) has no effect on CS-exposed NR8383 AM efferocytosis.
Data are presented as mean ± SEM, 1-way ANOVA, Sidak’s multiple comparisons test, * p<0.05, ** p<0.001, *** p<0.0001.
https://doi.org/10.1371/journal.pone.0176073.g001
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A1AT in the expression of several plasma membrane receptors [14, 28], we next investigated
whether A1AT alters the expression of efferocytosis receptors.
Effect of A1AT on AM efferocytosis receptors expression
A1AT modulation of neutrophil chemotaxis has been reported to occur via controlling mem-
brane expression of the Fc receptor FcγRIIIb [14], however A1AT effect and the mechanism
involved in membrane expression of efferocytosis receptors are not known. We first measured
the A1AT effect on MAR membrane expression in primary rat AM during ex vivo CS-expo-
sure. Under baseline conditions, A1AT treatment did not show a significant effect on MAR
expression on rat AM plasma membrane (data not shown). However, after CS exposure
Fig 2. Nebulized human A1AT effect on in situ efferocytosis in CS-exposed mice. Nebulized PBS or A1AT (Aralast
NP, 1mg/kg body weight, one individual dose or daily dose for 7 days, respectively) were administered to C57Bl/6 mice
prior to acute (3 h) or during the final week of chronic (6 mo) CS-exposure. In situ efferocytosis was quantified in the BAL
fluid after orotracheal instillation and co-incubation (1 h) with fluorescently labeled apoptotic thymocytes. Data are
presented as mean ± SEM, 2-way ANOVA, * p<0.05, ** p<0.001.
https://doi.org/10.1371/journal.pone.0176073.g002
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primary rat AM exhibited decreased MAR plasma membrane expression (Fig 3A and 3B) that
was significantly increased after A1AT (100 μg/mL, 16 h) treatment (Fig 3A and 3B). The
A1AT effect on MAR membrane expression was recapitulated in human AM isolated from the
BAL fluid of explanted lungs of non-smokers and active smokers individuals. AM recovered
from active smokers, but not AM recovered from non-smoker or ex-smokers with COPD indi-
viduals, showed increased MAR expression after ex vivo A1AT (100 μg/mL, 16 h) treatment
(Fig 3C).
Fig 3. Native A1AT effect on efferocytosis receptors expression and ADAM-17 (TACE) activity in CS-exposed AM. A-B.
Representative immunoblot (A) and densitometry (B, n = 4) of MAR expression in CS-exposed (3%, 4 h) and A1AT-treated (Aralast NP,
100 μg/mL, 16 h) primary rat AM. 1-way ANOVA, Sidak’s multiple comparisons test, * p<0.05. C. Representative immunoblots (n = 4) of MAR
expression in human AM isolated from the BAL of non-smoker and smoker individuals prior and after ex-vivo A1AT treatment (Prolastin C,
100 μg/mL, 16 h). D. A1AT treatment (Prolastin C, 100 μg/mL) time-dependently decreases TACE activity in the CS-exposed (10%, 4 h) THP-
1 membrane fraction. E. Representative immunoblot of MAR expression in the CS-exposed THP-1 cell lysates and supernatants after
treatment with A1AT (Prolastin C, 100 μg/mL, 30 min) or with a pharmacological inhibitor of TACE (TAPI-1, 50 μM, 30 min). F. Representative
immunoblot of MAR expression in the CS-exposed NR8383 AM cell lysates and supernatants after A1AT treatment (Prolastin C, 100 μg/mL,
16 h). The results are representative of 3 independent experiments. G-H. Representative immunoblot (G) and densitometry (H, n = 4) of PSR
expression in CS-exposed (10%, 4 h) and A1AT-treated (Aralast NP, 100 μg/mL, 16 h) NR8383 AM membrane fractions. I. Representative
immunoblots (n = 3) of PSR and SRB-2 expression in PiZZ-AM (13 μg protein equally loaded in each lane) after A1AT augmentation therapy
(Zemaira, CSL Behring, 60 mg/kg single dose or 120 mg/kg double dose). Note that doubling the weekly A1AT dose (visit 2) increases
PiZZ-AM A1AT intracellular abundance and PSR and SRB-2 expression levels vs. A1AT single dose (visit 1), effect that persist as carried over
effect after resuming single A1AT dose (visit 3).
https://doi.org/10.1371/journal.pone.0176073.g003
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An important mechanism to retain membrane receptors at plasma membrane is inhibition
of membrane sheddase TACE (ADAM-17) [29, 30]. We and others have shown that A1AT
inhibits TACE activity at plasma membrane in structural, e.g. endothelial cells [28] and
immune cells, e.g. neutrophils [14]. A1AT treatment inhibited in a time dependent manner
TACE activity in the membrane fraction of CS-exposed (10%, 4 h) THP1-derived macro-
phages (Fig 3D). Accordingly, treatment with A1AT (100 μg/mL, 30 min) or TNF-α Protease
Inhibitor-1 (TAPI-1, 50 μM/mL, 30 min) significantly decreased soluble MAR (sMAR) shed-
ding in the supernatant of CS-exposed THP-1-derived macrophages while increasing MAR
membrane expression (Fig 3E). These results were recapitulated in CS-exposed (10%, 4 h)
NR8383 AM treated with A1AT (100 μg/mL, 16 h) (Fig 3F).
Since several other specific (e.g. PSR, CD91) and facultative (e.g. SCARB-2, CD36, or
CD44) efferocytosis receptors are down regulated following in vivo and ex vivo CS-exposure
[31, 32], we next investigated whether A1AT supplementation increases their expression in
these conditions. We examined AM membrane expression of PSR and SCARB-2 after ex vivo
or in vivo A1AT therapy in CS-exposed NR8383 AM and in AATD patients. After CS exposure
NR8383 AM exhibited decreased PSR plasma membrane expression (Fig 3G and 3H) that was
significantly increased after A1AT (100 μg/mL, 16 h) treatment (Fig 3G and 3H). We noticed a
similar in vivo A1AT effect on PiZZ AM PSR and SRB-2 membrane expression where A1AT
double dose therapy increased efferocytosis receptors (visit 2) compared to levels after single
dose A1AT therapy (visit 1). The A1AT double dose effect persisted as carried over effect after
resuming single A1AT dose (visit 3) (Fig 3I).
Time-dependent effects of A1AT on phagocytosis and global scavenging
function of AM concomitantly exposed to Fc-coated and apoptotic
targets
Since A1AT improved both AM efferocytosis and the expression of efferocytosis receptors
during CS exposures, A1AT treatment may impart AM an anti-inflammatory functional phe-
notype. Previous studies have reported that AM anti-inflammatory programs activated by
efferocytosis have the potential to undesirably inhibit bacteria phagocytosis and killing [18].
We therefore interrogated the effect of A1AT on AM engulfment of Fc-coated targets, on
inducible NO synthase (iNOS) expression and TNF-α secretion, traits associated with AM’s
ability to effectively phagocytize bacterial targets.
A1AT treatment significantly improved phagocytosis of CS-exposed AM, as measured by
percentage engulfed fluorescently labeled Fc-coated, bacteria-like targets following 4h of
A1AT supplementation (Fig 4A). However, this beneficial effect did not persist at 16 h follow-
ing A1AT treatment (Fig 4A). Despite significant improvement in AM phagocytosis function,
A1AT treatment did not increase pro-inflammatory intracellular iNOS expression and TNF-α
secretion of LPS- and CS-exposed primary rat AM (Fig 4B and 4C).
We next determined the effect of A1AT on AM scavenging function in a complex environ-
ment, where both apoptotic and Fc-coated targets are present. While an inhibitory effect of
efferocytosis on phagocytosis has been previously described [18], the effect of Fc-coated target
phagocytosis on efferocytosis has not been reported. We measured the reciprocal effect of Fc
receptor-mediated engulfment (phagocytosis) on AM efferocytosis and determined the base-
line AM global scavenging function, defined as the proportion of AM that performed any tar-
get engulfment. In NR8383 AM, phagocytosis of Fc-coated targets suppressed in a dose-
dependent manner the proportion of AM that performed exclusively efferocytosis of apoptotic
targets (Fig 4D). To test whether the phagocytosis of larger Fc-coated targets has similar effects,
primary rat AM were concomitantly incubated with CTG-labeled Jurkat T-cells coated with
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IgG2a anti-human CD3 (larger size Fc-coated targets) and apoptotic targets. We noticed the
same marked inhibitory effect of phagocytosis on efferocytosis (Fig 4E). When AM were
treated with increasing apoptotic targets, as reported, efferocytosis dose-dependently inhibited
Fc receptor-mediated AM engulfment (phagocytosis) of Fc-coated targets (Fig 4F).
Ex-vivo CS exposure of primary rat AM simultaneously challenged with Fc-coated and apo-
ptotic targets decreased phagocytosis, efferocytosis, and the global engulfment of these cells
(Fig 4G). Treatment with A1AT (100 μg/mL, 16 h) treatment significantly increased the global
scavenging function of CS-exposed AM concomitantly challenged with Fc-coated and apopto-
tic targets (Fig 4G).
Fig 4. Native A1AT effect on CS-exposed AM phagocytosis and global scavenging function following concomitant Fc-coated
and apoptotic targets exposure. A-B. Relative phagocytosis index representing % of primary rat AM that engulfed fluorescently labeled
Fc-coated targets after CS-exposure (10%, 4 h) and A1AT treatment (Aralast NP, 100 μg/mL, 4 h), compared to AM engulfment in control
media. 1-way ANOVA, Sidak’s multiple comparisons test, * p<0.05. Note the lack of significant effect on phagocytosis at baseline (AC) or
during CS-exposure following 16 h of A1AT treatment. B-C. iNOS expression (B) and TNF-α secretion (C) in primary rat AM exposed to CS
(3%, 4 h) and treated with LPS (100 ng/mL, 4 h) and A1AT (Aralast NP, 100 μg/mL, 4 h). D. Higher Fc-coated to apoptotic targets ratio (0:1
to 10:1) dose-dependently inhibits NR8383 AM efferocytosis. E. Higher mouse anti-human CD3+ CTG-labeled Jurkat T-cells (Fc-coated
targets) to apoptotic targets ratio (0:1 to 5:1) dose-dependently inhibits primary rat AM efferocytosis. F. Higher apoptotic to Fc-coated
targets ratio (0:1 to 24:1) dose-dependently inhibits NR8383 AM phagocytosis. G. Overall engulfment [efferocytosis (E), phagocytosis (P),
and efferocytosis + phagocytosis (E+P)] of CS-exposed and A1AT-treated (Aralast NP, 100 μg/mL, 16 h) primary rat AM when
concomitantly exposed to apoptotic and Fc-coated targets at 1:1 ratio. 1-way ANOVA, Sidak’s multiple comparisons test, * p<0.05. Data
are presented as mean ± SEM.
https://doi.org/10.1371/journal.pone.0176073.g004
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Discussion
Our study identified that treatment with A1AT significantly improves efferocytosis, phago-
cytosis, and overall scavenging function of CS-exposed dysfunctional AM. This finding
may have clinical relevance to smokers and individuals with COPD with impaired AM scav-
enging function, which perpetuates pathogen persistence and lower airways bacterial colo-
nization linked to chronic inflammation, tissue damage, and frequent exacerbations [3].
These results indicate that native A1AT protein can be considered along with peroxisome
proliferator-activated receptor γ agonists, macrolide antibiotics, corticosteroids, statins,
and anti-oxidants as enhancer of AM engulfment of either pathogens or apoptotic targets
during CS exposure [1]. Whereas exogenous A1AT did not further augment the engulfment
function of healthy AM, a role of endogenous native A1AT in acute inflammatory and
repair phases of airway infections in otherwise healthy individuals remains to be investi-
gated. However, in smokers or in AATD, where the function and levels, respectively, of
endogenous A1AT may be suboptimal to stimulate airway bacteria and apoptotic cell clear-
ance, A1AT supplementation may be required to achieve functional A1AT levels that
restore AM engulfment.
A1AT stimulated efferocytosis of CS-exposed AM not only in ex vivo models, but also in
vivo, following exogenously administered apoptotic targets in CS-exposed C57BL/6J mice.
Since both increased efferocytosis and inhibition of apoptosis lower the abundance of apopto-
tic cells in tissues, our current results are congruent with our previous reports of decreased
apoptotic cells in lungs of animals exposed to pro-apoptotic stimuli and treated with exoge-
nous A1AT [33].
To our knowledge, we revealed for the first time that A1AT’s stimulatory effect on efferocy-
tosis was associated with increased abundance of AM receptors that recognize apoptotic tar-
gets, recognition required as first step for successful completion of efferocytosis. Unlike
complement- or Fc-mediated phagocytosis, which involve highly conserved, receptor-specific
engulfment of pathogens [2, 34], efferocytosis of apoptotic targets involves a wide array of
receptors—MAR, SRB-2, PSR, CD36, LDL-rp, CD44 and bridging molecules—Milk-fat-glob-
ule-factor (MFG-E8), Gas6, thrombospondin, β2 glycoprotein-I, protein S, and annexin I [1].
Consistent with studies by Hodge et al., we found decreased levels of MAR, PSR, and SRB-2
on AM exposed to CS, associated with impaired AM efferocytosis in active smokers and
COPD individuals [31, 35, 36]. A1AT treatment significantly increased these receptor levels in
human AM from active smokers, AATD individuals, and in CS-exposed primary rat and
NR8383 AM. Moreover, A1AT treatment decreased sMAR shedding from the plasma mem-
brane of CS-exposed AM, consistent with TACE-inhibition by the serpin, a non-canonical
function shown by others and us in PMN [14], endothelial cells [28], respectively, and now
demonstrated here in AM. While this association does not prove causality, the evidence that
MAR is cleaved by TACE [30], that TACE is inhibited by A1AT [14, 28], and that A1AT
decreases sMAR shedding and increases MAR’s plasma membrane abundance highly suggests
that TACE inhibition by A1AT is a central mechanism accounting for enhanced efferocytosis.
However, the mechanisms by which A1AT enhances Fc-engulfment or phagocytosis remain
elusive. One potential candidate mechanism is preservation of Fc -receptor complex at the
plasma membrane as suggested by Bergin et al., who demonstrated A1AT-mediated TACE
inhibition was associated with increased FcγRIIIb expression on neutrophils membrane and
decreased neutrophil chemotaxis [14]. Another putative mechanism may be explained by
direct functional interaction of A1AT with complement protein, C3b as recently reported in
abstract form [37] and may enhance phagocytosis of opsonized bacterial targets via comple-
ment receptors pathway.
A1AT improves cigarette smoke-exposed macrophages engulfment
PLOS ONE | https://doi.org/10.1371/journal.pone.0176073 April 27, 2017 13 / 17
A novel observation reported in this study is that when AM are simultaneously challenged
with both apoptotic and phagocytic targets, each target inhibits the effectiveness of overall AM
engulfment. Whereas exposure to CS further inhibits, A1AT treatment improves overall AM
engulfment even during this complex engulfment environment. Although our ex vivo model
cannot be directly extrapolated to chronic airway inflammatory conditions—e.g. COPD,
AATD, cystic fibrosis, or severe asthma, the airways of affected patients frequently contain
both bacteria (e.g. Haemophilus influenza, Pseudomonas aeruginosa, or Staphylococcus aureus)
and a large burden of apoptotic cells [38–41]. Our findings, which require validation in an in
vivo model, are not surprising, since Medeiros et al. have demonstrated that apoptotic cells
suppress bacteria phagocytosis in a mouse model of pneumococcal pneumonia [18]. On the
other hand, our group and others have published that bacterial released products like alginate
and pyocynin dampen the ability of AM to scavenge apoptotic targets [26, 42].
Interestingly, a significantly increased phagocytosis was only noted shortly after A1AT sup-
plementation (4 h), but not after prolonged (16 h) treatment, whereas the reverse was true for
enhancement of efferocytosis. This suggests differential, time-dependent effect of A1AT on
cell function. We and others have noted similar biphasic effects of A1AT on endothelial cells
[28] and macrophages (PBDM) responses to inflammation [43]. In the latter, Subramaniyam
et al. have demonstrated that A1AT administration enhanced LPS-induced TNF-α, IL-6, and
IL-8 release at 4 h from human monocytes and neutrophils, but A1AT delayed effect was not
investigated [43]. The mechanisms behind these time-dependent effects require further clarifi-
cation, as they may determine the timing and frequency of A1AT supplementation for various
clinical indications.
Nebulized A1AT has been successfully tested in patients with cystic fibrosis and showed
that A1AT treatment decreases sputum anti-elastase activity, airway bacterial or neutrophil
load in the CF lung [44]. Based on these reports and our current findings of enhanced AM
scavenging function without further incitement of inflammation, administration of A1AT to
the airways may be considered for active smokers with acute lung bacterial infections to reduce
exacerbation duration, severity, and time to recovery.
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